person · Reporting owner
BISCHOFBERGER NORBERT W
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | EVP, R&D and CSO | February 15, 2018 | February 23, 2018 |
| Vir Biotechnology, Inc.VIR · Entity 4522 | Director | May 27, 2026 | May 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date February 15, 2018 · Filed February 23, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,602 |
Ending reported balance
After 2018-02-21 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2018-02-15 · Grant · Acquired 340 · Balance 12,793 F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Row 2 · 2018-02-21 · Grant · Acquired 16,468 · Balance 29,261 F2: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 1, 2016, and February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2018 and December 31, 2019, respectively. Row 3 · 2018-02-21 · Grant · Acquired 6,805 · Balance 36,066 F3: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2015. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Row 4 · 2018-02-21 · Tax withholding · Disposed 7,071 · Balance 28,995 Row 5 · 2018-02-21 · Gift · Disposed 9,393 · Balance 19,602 F4: Shares gifted to family trust. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 2,317,800 |
Reported balance
After 2018-02-21 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2018-02-21 · Gift · Acquired 9,393 · Balance 2,317,800 F4: Shares gifted to family trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.
F2: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 1, 2016, and February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2018 and December 31, 2019, respectively.
F3: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2015. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors.
F4: Shares gifted to family trust.
Vir Biotechnology, Inc.
Report date May 27, 2026 · Filed May 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,333 |
Reported balance
After 2026-05-27 transaction · row 1
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 8,000 · Balance 21,333 F1: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. F2: The RSUs will vest in full on May 27, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.10 · Expires 2036-05-26 | Direct | 16,000 |
Reported balance
After 2026-05-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-27 · Grant · Acquired 16,000 · Balance 16,000 F4: The shares subject to the stock option will vest and become exercisable in full on May 27, 2027. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 10,667 |
Reported balance
Holding disclosure · report date 2026-05-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 10,667 F3: The shares are held in the name of Nextquest, LLC, of which the Reporting Person is a managing member. |
Filing footnotes · ownership attribution and instrument terms
F1: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.
F2: The RSUs will vest in full on May 27, 2027.
F3: The shares are held in the name of Nextquest, LLC, of which the Reporting Person is a managing member.
F4: The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Kronos Bio, Inc.
Report date June 20, 2025 · Filed June 20, 2025
Section 16 reporting ended · disclosed 2025-06-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2025-06-20 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-06-20 · Other · Disposed 10,802,138 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. F3: By the Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994, |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2025-06-20 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-06-20 · Other · Disposed 263,750 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. F4: By the Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The David Michael Anthony Dynasty GST Exempt Trust dated April 29, 2020. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2025-06-20 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2025-06-20 · Other · Disposed 263,750 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. F5: By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The David Michael Anthony Dynasty GST Non-Exempt Trust dated April 29, 2020. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2025-06-20 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2025-06-20 · Other · Disposed 263,750 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. F6: By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The Irene Alisha Bischofberger Dynasty GST Exempt Trust dated April 29, 2020. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2025-06-20 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2025-06-20 · Other · Disposed 263,750 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. F7: By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The Irene Alisha Bischofberger Dynasty GST Non-Exempt Trust dated April 29, 2020. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.78 · Expires 2030-12-09 | Direct | 0 |
Reported balance
After 2025-06-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-06-20 · Disposition to issuer · Disposed 297,186 · Balance 0 F8: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.30 · Expires 2032-02-15 | Direct | 0 |
Reported balance
After 2025-06-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-06-20 · Disposition to issuer · Disposed 400,000 · Balance 0 F8: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.09 · Expires 2033-02-14 | Direct | 0 |
Reported balance
After 2025-06-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-06-20 · Disposition to issuer · Disposed 570,868 · Balance 0 F8: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.08 · Expires 2034-02-14 | Direct | 0 |
Reported balance
After 2025-06-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-06-20 · Disposition to issuer · Disposed 699,800 · Balance 0 F8: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2]
F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.
F3: By the Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994,
F4: By the Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The David Michael Anthony Dynasty GST Exempt Trust dated April 29, 2020.
F5: By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The David Michael Anthony Dynasty GST Non-Exempt Trust dated April 29, 2020.
F6: By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The Irene Alisha Bischofberger Dynasty GST Exempt Trust dated April 29, 2020.
F7: By Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of The Irene Alisha Bischofberger Dynasty GST Non-Exempt Trust dated April 29, 2020.
F8: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.
Morphic Holding, Inc.
Report date August 16, 2024 · Filed August 20, 2024
Section 16 reporting ended · disclosed 2024-08-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2029-06-26 | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-08-16 · Disposition to issuer · Disposed 24,000 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company Stock Option ("Option") is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.96 · Expires 2030-06-18 | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-08-16 · Disposition to issuer · Disposed 12,000 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company Stock Option ("Option") is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $64.79 · Expires 2031-06-16 | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-08-16 · Disposition to issuer · Disposed 9,888 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company Stock Option ("Option") is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.49 · Expires 2032-06-08 | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-08-16 · Disposition to issuer · Disposed 17,550 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company Stock Option ("Option") is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.47 · Expires 2033-05-31 | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-08-16 · Disposition to issuer · Disposed 12,535 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company Stock Option ("Option") is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.52 · Expires 2034-06-03 | Direct | 0 |
Reported balance
After 2024-08-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-08-16 · Disposition to issuer · Disposed 23,168 · Balance 0 F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding. F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F5: The Option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the "Issuer" or the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent ("Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.
F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased by Purchaser for $57.00 per share (the "Offer Price"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding.
F3: The Company Stock Option ("Option") is fully vested.
F4: Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option") became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof.
F5: The Option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2013 Filed Sep 18, 2013 20:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock option (right to buy) · Derivative | 90,000 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001179110-13-014318 · edgar.xml · derivative · entry 4 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 90,000 shares Expires 2016-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| September 16, 2013 Filed Sep 18, 2013 20:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 6,427 | $63.93 | $410,876.18 |
DisclosureSEC source: 0001179110-13-014318 · edgar.xml · nonDerivative · entry 3 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,159,643 F4 · price: Sale prices reported for the transactions reported here range from $63.62 to $64.15. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| September 16, 2013 Filed Sep 18, 2013 20:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 83,573 | $63.05 | $5,269,085.43 |
DisclosureSEC source: 0001179110-13-014318 · edgar.xml · nonDerivative · entry 2 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,166,070 F3 · price: Sale prices reported for the transactions reported here range from $62.60 to $63.60. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| September 16, 2013 Filed Sep 18, 2013 20:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 90,000 | $14.50 | $1,305,225.00 |
DisclosureSEC source: 0001179110-13-014318 · edgar.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,249,643 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 14, 2013 Filed Aug 16, 2013 16:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock option (right to buy) · Derivative | 90,000 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001179110-13-013212 · edgar.xml · derivative · entry 4 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 540,000 Underlying: Common Stock · 90,000 shares Expires 2016-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| August 14, 2013 Filed Aug 16, 2013 16:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 9,193 | $59.29 | $545,033.66 |
DisclosureSEC source: 0001179110-13-013212 · edgar.xml · nonDerivative · entry 3 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,159,643 F4 · price: Sale prices reported for the transactions reported here range from $59.15 to $59.54. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| August 14, 2013 Filed Aug 16, 2013 16:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 80,807 | $58.71 | $4,743,847.66 |
DisclosureSEC source: 0001179110-13-013212 · edgar.xml · nonDerivative · entry 2 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,168,836 F3 · price: Sale prices reported for the transactions reported here range from $58.15 to $59.14. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| August 14, 2013 Filed Aug 16, 2013 16:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 90,000 | $14.50 | $1,305,225.00 |
DisclosureSEC source: 0001179110-13-013212 · edgar.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,249,643 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2013 Filed Jul 18, 2013 00:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock option (right to buy) · Derivative | 90,000 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001179110-13-011881 · edgar.xml · derivative · entry 3 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 630,000 Underlying: Common Stock · 90,000 shares Expires 2016-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| July 15, 2013 Filed Jul 18, 2013 00:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 90,000 | $57.33 | $5,160,132.00 |
DisclosureSEC source: 0001179110-13-011881 · edgar.xml · nonDerivative · entry 2 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,159,643 F3 · price: Sale prices reported for the transactions reported here range from $56.83 to $57.62. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| July 15, 2013 Filed Jul 18, 2013 00:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 90,000 | $14.50 | $1,305,225.00 |
DisclosureSEC source: 0001179110-13-011881 · edgar.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,249,643 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 26, 2013 Filed Oct 22, 2013 20:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 265,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-015676 · edgar.xml · nonDerivative · entry 10 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 2,162,681 F1 · ownership.nature: Shares gifted to family trust. Read SEC document |
| April 26, 2013 Filed Oct 22, 2013 20:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 265,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-015676 · edgar.xml · nonDerivative · entry 5 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| April 25, 2013 Filed Oct 22, 2013 20:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 265,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-015676 · edgar.xml · nonDerivative · entry 9 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 1,897,348 F1 · ownership.nature: Shares gifted to family trust. Read SEC document |
| April 25, 2013 Filed Oct 22, 2013 20:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 265,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-015676 · edgar.xml · nonDerivative · entry 4 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,333 Read SEC document |
| April 24, 2013 Filed Oct 22, 2013 20:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 265,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-015676 · edgar.xml · nonDerivative · entry 8 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 1,631,848 F1 · ownership.nature: Shares gifted to family trust. Read SEC document |
| April 24, 2013 Filed Oct 22, 2013 20:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 265,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-015676 · edgar.xml · nonDerivative · entry 3 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 530,833 Read SEC document |
| April 23, 2013 Filed Oct 22, 2013 20:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 265,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-015676 · edgar.xml · nonDerivative · entry 7 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 1,366,348 F1 · ownership.nature: Shares gifted to family trust. Read SEC document |
| April 23, 2013 Filed Oct 22, 2013 20:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 265,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-015676 · edgar.xml · nonDerivative · entry 2 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 796,333 Read SEC document |
| April 09, 2013 Filed Oct 22, 2013 20:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 1,097,810 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-015676 · edgar.xml · nonDerivative · entry 6 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 1,100,848 F1 · ownership.nature: Shares gifted to family trust. Read SEC document |
| April 09, 2013 Filed Oct 22, 2013 20:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 1,097,810 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-015676 · edgar.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,061,833 Read SEC document |
| March 06, 2013 Filed Mar 8, 2013 19:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 12,523 | $45.40 | $568,544.20 |
DisclosureSEC source: 0001179110-13-004635 · edgar.xml · nonDerivative · entry 2 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,159,643 Read SEC document |
| March 06, 2013 Filed Mar 8, 2013 19:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-004635 · edgar.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,172,166 F1 · shares: Vesting of performance share awards on March 6, 2013 F2 · balance_after: Amount of securities beneficially owned following the reported transaction includes 968 shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan on February 15, 2013. Read SEC document |
| February 01, 2013 Filed Feb 5, 2013 22:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 134,660 | $0.00 Strike: $40.56 | $0.00 |
DisclosureSEC source: 0001179110-13-001942 · edgar.xml · derivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,660 Underlying: Common Stock · 134,660 shares Expires 2023-02-01 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| January 30, 2013 Filed Jan 24, 2014 22:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 26,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-001361 · edgar.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,666 F1 · shares: Represents shares of the Issuer's common stock subject to a specific tranche of the performance share award made to the Reporting Person on January 26, 2012. Such tranche of shares was subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was deemed satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be actually issued to the Reporting Person until such individual satisfies the applicable service-vesting requirement by continuing in the Issuer's employ through December 31, 2014. Read SEC document |
| November 27, 2012 Filed Dec 20, 2012 17:48 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 2,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-018031 · edgar.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,073,599 F1 · kind: Shares gifted to organizations under which Mr. Bischofberger has no beneficial ownership Read SEC document |
| June 29, 2012 Filed Jul 3, 2012 23:18 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 733 | $29.02 | $21,270.93 |
DisclosureSEC source: 0001179110-12-011184 · edgar.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,076,219 F1 · kind: Amount of securities beneficially owned following the reported transaction includes 733 shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan on June 29, 2012. Read SEC document |
| March 12, 2012 Filed Mar 14, 2012 23:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 8,767 | $46.16 | $404,684.72 |
DisclosureSEC source: 0001179110-12-005057 · edgar.xml · nonDerivative · entry 2 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,075,486 Read SEC document |
| March 12, 2012 Filed Mar 14, 2012 23:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 19,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-005057 · edgar.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,084,253 F1 · shares: Issuance of common stock upon vesting of performance share awards on March 12, 2012 Read SEC document |
| March 15, 2011 Filed Mar 17, 2011 23:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 7,876 | $39.79 | $313,386.04 |
DisclosureSEC source: 0001179110-11-005188 · edgar.xml · nonDerivative · entry 2 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,061,922 Read SEC document |
| March 15, 2011 Filed Mar 17, 2011 23:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 16,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-11-005188 · edgar.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,069,798 F1 · shares: Issuance of common stock upon vesting of certain performance share awards on March 15, 2011. Read SEC document |
| March 15, 2011 Filed Apr 6, 2011 23:31 UTC Amendment | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 9,452 | $39.79 | $376,095.08 |
DisclosureSEC source: 0001179110-11-006158 · edgar.xml · nonDerivative · entry 2 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,063,721 F2 · shares: The transactions listed in Table 1 are restated in its entirety to show the correct number of shares issued and beneficially owned. Read SEC document |
| March 15, 2011 Filed Apr 6, 2011 23:31 UTC Amendment | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 20,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-11-006158 · edgar.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,073,173 F1 · shares: Issuance of common stock upon vesting of certain performance share awards on March 15, 2011. F2 · shares: The transactions listed in Table 1 are restated in its entirety to show the correct number of shares issued and beneficially owned. Read SEC document |
| January 20, 2011 Filed Jan 25, 2011 00:55 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 119,000 | $0.00 Strike: $38.17 | $0.00 |
DisclosureSEC source: 0001179110-11-001273 · edgar.xml · derivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,000 Underlying: Common Stock · 119,000 shares Expires 2021-01-20 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on January 20, 2012 the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested on January 20, 2015. The options expire on January 20, 2021. Read SEC document |
| January 20, 2011 Filed Jan 30, 2012 23:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 116,250 | $0.00 Strike: $48.59 | $0.00 |
DisclosureSEC source: 0001179110-12-001317 · edgar.xml · derivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,250 Underlying: Common Stock · 116,250 shares Expires 2022-01-26 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| November 08, 2010 Filed Nov 25, 2010 00:34 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 5,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-016624 · edgar.xml · nonDerivative · entry 2 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 1,519 F1 · kind: Shares were given as gifts to a total of 6 charitable organizations. Read SEC document |
| March 08, 2010 Filed Mar 11, 2010 01:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 12,136 | $47.01 | $570,513.36 |
DisclosureSEC source: 0001179110-10-004956 · edgar.xml · nonDerivative · entry 2 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,052,346 Read SEC document |
| March 08, 2010 Filed Mar 11, 2010 01:28 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 26,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-004956 · edgar.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,064,482 F1 · shares: Issuance of common stock upon vesting of certain performance share awards on March 8, 2010. Read SEC document |
| February 24, 2010 Filed Feb 26, 2010 22:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 53,754 | $0.00 Strike: $16.01 | $0.00 |
DisclosureSEC source: 0001179110-10-003973 · edgar.xml · derivative · entry 8 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 53,754 shares Expires 2015-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options had a five year vesting schedule. 20% of the options vested on January 26, 2006, the first anniversary date of the grant. The balance vested 5% every three months thereafter until fully vested on January 26, 2010. Read SEC document |
| February 24, 2010 Filed Feb 26, 2010 22:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 6,246 | $0.00 Strike: $16.01 | $0.00 |
DisclosureSEC source: 0001179110-10-003973 · edgar.xml · derivative · entry 7 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,246 shares Expires 2015-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options had a five year vesting schedule. 20% of the options vested on January 26, 2006, the first anniversary date of the grant. The balance vested 5% every three months thereafter until fully vested on January 26, 2010. Read SEC document |
| February 24, 2010 Filed Feb 26, 2010 22:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 53,754 | $47.49 | $2,552,589.32 |
DisclosureSEC source: 0001179110-10-003973 · edgar.xml · nonDerivative · entry 3 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,038,482 F1 · price: Sale prices reported for the transactions reported here range from $47.45 to $47.51. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| February 24, 2010 Filed Feb 26, 2010 22:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 53,754 | $16.01 | $860,601.54 |
DisclosureSEC source: 0001179110-10-003973 · edgar.xml · nonDerivative · entry 2 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,092,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2010 Filed Feb 26, 2010 22:54 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 6,246 | $16.01 | $99,998.46 |
DisclosureSEC source: 0001179110-10-003973 · edgar.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,038,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2010 Filed Feb 2, 2010 00:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 72,000 | $0.00 Strike: $47.51 | $0.00 |
DisclosureSEC source: 0001179110-10-001746 · edgar.xml · derivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Stock · 72,000 shares Expires 2020-01-28 F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options will vest on January 28, 2011 the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on January 28, 2015. Read SEC document |
| November 12, 2009 Filed Nov 17, 2009 01:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $16.01 | $0.00 |
DisclosureSEC source: 0001179110-09-015569 · edgar.xml · derivative · entry 8 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,754 Underlying: Common Stock · 30,000 shares Expires 2015-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The options had a five year vesting schedule. 20% of the options vested on January 26, 2006, the first anniversary date of the grant. The balance vested 5% every three months thereafter until fully vested on January 26, 2010. Read SEC document |
| November 12, 2009 Filed Nov 17, 2009 01:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GiftCommon Stock | 5,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-09-015569 · edgar.xml · nonDerivative · entry 5 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 6,794 Read SEC document |
| November 12, 2009 Filed Nov 17, 2009 01:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,000 | $47.16 | $94,319.00 |
DisclosureSEC source: 0001179110-09-015569 · edgar.xml · nonDerivative · entry 4 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 12,394 Read SEC document |
| November 12, 2009 Filed Nov 17, 2009 01:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 17,920 | $47.16 | $845,098.24 |
DisclosureSEC source: 0001179110-09-015569 · edgar.xml · nonDerivative · entry 3 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,032,236 F3 · price: Sale prices reported for the transactions reported here range from $47.10 to $47.26. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 12, 2009 Filed Nov 17, 2009 01:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 30,000 | $46.91 | $1,407,348.00 |
DisclosureSEC source: 0001179110-09-015569 · edgar.xml · nonDerivative · entry 2 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,050,156 F1 · price: Sale prices reported for the transactions reported here range from $46.75 to $47.00. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 12, 2009 Filed Nov 17, 2009 01:03 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 30,000 | $16.01 | $480,300.00 |
DisclosureSEC source: 0001179110-09-015569 · edgar.xml · nonDerivative · entry 1 BISCHOFBERGER NORBERT W · CIK 0001190273 · EVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,080,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.